Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide Dose-Finding in T2DM
NCT02057172Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Oct 2014
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efpeglenatide in type 2 diabetes mellitus (T2DM), sponsored by Hanmi Pharmaceutical. Started Jan 2014; status: completed.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02057172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057172.